<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336638">
  <stage>Registered</stage>
  <submitdate>25/03/2011</submitdate>
  <approvaldate>28/03/2011</approvaldate>
  <actrnumber>ACTRN12611000328976</actrnumber>
  <trial_identification>
    <studytitle>Nuclear Perfusion Tomography for the Assessment of the Pulmonary Circulation</studytitle>
    <scientifictitle>Nuclear Perfusion Tomography for the Assessment of the Pulmonary Circulation</scientifictitle>
    <utrn>U1111-1119-9337</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pulmonary Hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will undergo a single photon emission computed tomography lung perfusion scan using technetium labelled macroaggregated albumin. The duration of the scan is approximately 30 minutes. All participant groups (healthy controls, high-risk for pulmonary arterial hypertension, and established pulmonary hypertension) will undergo the same intervention.</interventions>
    <comparator>Healthy control group are adults age &gt;18 with no history or lung or heart disease; and no risk factors for pulmonary arterial hypertension (ie scleroderma/connective tissue disease, previous thromboembolic disease, relative of idiopathic pulmonary arterial hypertension, HIV infection). The healthy control group will receive the same intervention in the study.</comparator>
    <control>Active</control>
    <interventioncode>Early detection / Screening</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Distribution of pulmonary perfusion will be analysed via software programme. (ITT Visual Systems, Boulder CO, USA)</outcome>
      <timepoint>Baseline</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Normalised lung perfusion volume will be analysed via software programme. (ITT Visual Systems, Boulder CO, USA)</outcome>
      <timepoint>Baseline</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Control group
- No history of cardiac or respiratory disease
- Normal spirometry
- Normal transthoracic echocardiogram
- Smoking history &lt; 10 years
- No risk factor for pulmonary hypertension

2. High Risk for PAH Group
- History of scleroderma or carrier of BMPR2 mutation
- Normal resting pulmonary artery pressure 
- No significant lung disease

2. Pulmonary arterial hypertension (PAH) group
- WHO Classification Group 1 PAH
- Pre-capillary pulmonary arterial hypertension confirmed on Right Heart Catheter: mean pulmonary &gt; 25 mm Hg and wedge pressure &lt;15 mm Hg</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Case control</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/04/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>36</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2050</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>David Celermajer</primarysponsorname>
    <primarysponsoraddress>Department of Cardiology
Royal Prince Alfred Hospital
Missenden Road
Camperdown 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Sydney</fundingname>
      <fundingaddress>Faculty of Medicine
Central Clinical School
University of Sydney
Camperdown 2050</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Edmund Lau</sponsorname>
      <sponsoraddress>Department of Cardiology
Royal Prince Alfred Hospital
Missenden Road
Camperdown 2050</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dale Bailey</othercollaboratorname>
      <othercollaboratoraddress>Department of Nuclear Medicine
Royal North Shore Hospital
Pacific Highway 
St Leonards</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Pulmonary arterial hypertension (PAH) is a devastating condition with a poor prognosis. There are currently no widely available imaging modality to assess lung perfusion, which is decreased in PAH. Single photon emission computed tomography (SPECT) is a nuclear medicine technique which can assess three dimensional lung perfusion. We wish to evaluate the utility of SPECT in the assessment and early detection of PAH.</summary>
    <trialwebsite>Nil</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>SSWAHS Ethics Review Committee (RPAH Zone)</ethicname>
      <ethicaddress>Royal Prince Alfred Hospital
Missenden Road
Camperdown NSW 2050</ethicaddress>
      <ethicapprovaldate>18/11/2010</ethicapprovaldate>
      <hrec>HREC/10/RPAH/505</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Edmund Lau</name>
      <address>Department of Cardiology
Royal Prince Alfred Hospital
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 9515 6794</phone>
      <fax>+61 2 9546 6870</fax>
      <email>edmundmtlau@gmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Edmund Lau</name>
      <address>Department of Cardiology
Royal Prince Alfred Hospital
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 9515 6794</phone>
      <fax>+61 2 9546 6870</fax>
      <email>edmundmtlau@gmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Edmund Lau</name>
      <address>Department of Cardiology
Royal Prince Alfred Hospital
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 9515 6794</phone>
      <fax>+61 2 9546 6870</fax>
      <email>edmundmtlau@gmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>